PharmaEssentia Corporation

TWSE:6446 Rapporto sulle azioni

Cap. di mercato: NT$226.7b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

PharmaEssentia Gestione

Gestione criteri di controllo 3/4

PharmaEssentia's Il CEO è Ko-Chung Lin, nominato in Jan2017, ha un mandato di 7.58 anni. possiede direttamente 1.62% delle azioni della società, per un valore di NT$ 3.73B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 3 anni.

Informazioni chiave

Ko-Chung Lin

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO7.7yrs
Proprietà del CEO1.6%
Durata media del management4.9yrs
Durata media del Consiglio di amministrazione3.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

Aug 20
We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Apr 02
Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

Mar 18
Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 06
PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Mar 04
Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

PharmaEssentia (GTSM:6446) Is Using Debt Safely

Feb 10
PharmaEssentia (GTSM:6446) Is Using Debt Safely

What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 06
What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

Nov 30
PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ko-Chung Lin rispetto agli utili di PharmaEssentia?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

NT$1b

Mar 31 2024n/an/a

NT$442m

Dec 31 2023n/an/a

-NT$624m

Sep 30 2023n/an/a

-NT$890m

Jun 30 2023n/an/a

-NT$1b

Mar 31 2023n/an/a

-NT$2b

Dec 31 2022n/an/a

-NT$1b

Sep 30 2022n/an/a

-NT$2b

Jun 30 2022n/an/a

-NT$2b

Mar 31 2022n/an/a

-NT$3b

Dec 31 2021NT$9mNT$9m

-NT$3b

Sep 30 2021n/an/a

-NT$3b

Jun 30 2021n/an/a

-NT$3b

Mar 31 2021n/an/a

-NT$2b

Dec 31 2020NT$9mNT$9m

-NT$2b

Sep 30 2020n/an/a

-NT$1b

Jun 30 2020n/an/a

-NT$862m

Mar 31 2020n/an/a

-NT$856m

Dec 31 2019NT$9mNT$8m

-NT$843m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Ko-Chung sia ragionevole rispetto ad aziende di dimensioni simili nel mercato TW.

Compensazione vs guadagni: La retribuzione di Ko-Chung è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Ko-Chung Lin

7.7yrs

Mandato

NT$9,389,000

Compensazione

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12yrsNT$8.49m1.05%
NT$ 2.4b
Ko-Chung Lin
Founder7.7yrsNT$9.39m1.62%
NT$ 3.7b
Chan-Kou Hwang
Presidentno dataNT$8.49m0.61%
NT$ 1.4b
Snow Chang
Accounting Manager & Senior Manager of Finance8.9yrsNessun datoNessun dato
Samuel Lin
VP and Head of Business Operations & Strategy2.7yrsNessun datoNessun dato
Lih-Ling Lin
Chief Scientific Officer2.1yrsNessun dato0.010%
NT$ 23.3m
Rachel Lipsitz
VP and Head of Corporate Communications & Advocacy2.7yrsNessun datoNessun dato
Roddy Mcilwain
Senior VP and Head of Sales & Marketing3.7yrsNessun datoNessun dato
Anjana Pursnani
Senior VP & Head of People2.7yrsNessun datoNessun dato
Albert Qin
Chief Medical Officer7.7yrsNessun dato0.0061%
NT$ 13.9m
Narihisa Miyachi
Head of Japan Medical Affairs6.2yrsNessun datoNessun dato
Yen-Tung Luan
Chief Operating Officer of Taichung Plant6.2yrsNessun datoNessun dato

4.9yrs

Durata media

Gestione esperta: Il team dirigenziale di 6446 è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12yrsNT$8.49m1.05%
NT$ 2.4b
Ko-Chung Lin
Founder3.1yrsNT$9.39m1.62%
NT$ 3.7b
Chan-Kou Hwang
President9.3yrsNT$8.49m0.61%
NT$ 1.4b
Jeffrey R. Williams
Independent Directorless than a yearNessun datoNessun dato
Ching-Tsun Liu
Independent Directorless than a yearNessun dato0.13%
NT$ 288.3m
Jinn-Der Chang
Independent Director10.5yrsNT$120.00k0.029%
NT$ 65.5m
Jien-Heh Tien
Independent Director6.3yrsNT$120.00k0.00060%
NT$ 1.4m
Ming-Chuan Hsieh
Independent Directorless than a yearNessun dato0.0012%
NT$ 2.7m
Norio Komatsu
Chairperson of Japan3.3yrsNessun datoNessun dato
Shen Yi Li
Director3.1yrsNT$95.00k0.25%
NT$ 555.7m
HsuehFang Hsu
Directorless than a yearNessun datoNessun dato
ChenJung Hsiao
Directorless than a yearNessun datoNessun dato

3.1yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6446 sono considerati esperti (durata media dell'incarico 3 anni).